Glucosaminylmuramyl dipeptide potentiates the effects of tumor necrosis factor-alpha and cisplatin on transformed cells in vitro.
We studied the effect of combined treatment with cisplatin, glucosaminylmuramyl dipeptide, and TNF-alpha on viability of MCF-7, U-937, B16, and L-929 tumor cells, Ehrlich ascites carcinoma cells, and normal cells (human peripheral blood lymphocytes, peritoneal macrophages, and mouse bone marrow cells). Glucosaminylmuramyl dipeptide was nontoxic for normal and tumor cells, but promoted death of tumor cells after administration in combination with cisplatin and/or TNF-alpha. At the same time, glucosaminylmuramyl dipeptide did not modulate the cytotoxic effect of individual or combined treatment with cisplatin and TNF-alpha on normal cells. Administration of glucosaminylmuramyl dipeptide to cultured MCF-7 cells 20 h before the study increased the potentiating effect of muramyl peptide.
Petrova
E E
EE
Laboratory of Immunochemistry, M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow.
Valyakina
T I
TI
Komaleva
R L
RL
Simonova
M A
MA
Nesmeyanov
V A
VA
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002945:Cisplatin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D017737:Macrophages, Peritoneal / Q000166:cytology / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D020298:U937 Cells
D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C063429:glucosaminylmuramyl-2-alanine-D-isoglutamine; D002945:Cisplatin